Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection

Inclusion Criteria: * Patients with a first diagnosis of HCC who have undergone a curative resection * Radiologic evidence of disease free ≥4 weeks after complete surgical resection * Full recovery from surgical resection or post-operative transarterial chemoembolization before randomization * Randomization needs to occur within 12 weeks of the date of surgical resection * High risk for HCC recurrence as protocol defined * Child-Pugh Score, Class A * ECOG performance status 0 or 1 * No prior systemic anticancer therapy for HCC * Adequate hematologic and organ function Exclusion Criteria: * Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC * Evidence of residual, recurrent, or metastatic disease at randomization * History of hepatic encephalopathy or organ transplantation * Patients who are in the waiting list for liver transplantation * Patients with Vp4 portal vein thrombosis * Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or other immunotherapy * Pregnant or lactating women